Sustained relief of chronic pain: Pharmacokinetics of sustained release morphine

Clinical Pharmacokinetics

Volumn 35, Issue 3, 1998, Pages 173-190

  Gourlay, Geoffrey K ^a  

^a FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MORPHINE; MORPHINE SULFATE;

ANALGESIA; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CHRONIC PAIN; DRUG BLOOD LEVEL; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECTAL DRUG ADMINISTRATION; SUSTAINED RELEASE FORMULATION;

ADMINISTRATION, ORAL; ADMINISTRATION, RECTAL; ANALGESICS, OPIOID; CHEMISTRY, PHARMACEUTICAL; CHILD; DELAYED-ACTION PREPARATIONS; FOOD-DRUG INTERACTIONS; HUMANS; MORPHINE; PAIN;

EID: 0031680019     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199835030-00002     Document Type: Article

References (66)

1. Traynor JR. The μ-opioid receptor. Pain Rev 1996; 3: 221-48
2. Simonin F, Gaveriaux-Ruff C, Befort K, et al. κ-opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology and expression pattern in the nervous system. Proc Natl Acad Sci U S A 1995; 92: 7006-10
3. Befort K, Kieffer BL. Structure-activity relationships in the δ-opioid receptor. Pain Rev 1997; 4: 100-21
4. Clausen TG. International opioid consumption. Acta Anaesthesiol Scand 1997; 41: 162-5
5. Richards AH. The use of controlled release morphine sulfate (MS Contin) in Queensland 1990-1993. Med J Aust 1995; 163: 181-2
6. Graziotti PJ, Goucke CR. The use of oral opioids in patients with chronic non-cancer pain: management strategies. Med J Aust 1996; 167: 30-4
7. Schug SA, Merry AF, Acland RH. Treatment principles for the use of opioids in pain of non-malignant origin. Drugs 1991; 42: 228-32
8. Maddox JD, Joranson D, Angarola RT, et al. The use of opioids for the treatment of chronic pain [position statement]. Clin J Pain 1997; 13: 6-8
9. Angarola RT, Wray SD. Legal Impediments to cancer pain treatment. In: Hill Jr CS, Fields WS, editors. Advances in pain research and therapy. Vol. 11. New York: Raven Press, 1989: 213-31
10. Twycross RG, Lack SA. Oral morphine in advanced cancer. Beaconsfield: Beaconsfield Publishers, 1984
11. Gourlay GK, Cherry DA, Cousins MJ. A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. Pain 1986; 25: 297-312
12. Hill HF, Chapman CR, Saeger LS, et al. Steady-state infusions of opioids in human: II. Concentration-effect relationships and therapeutic margins. Pain 1990; 43: 69-79
13. Gourlay GJ, Kowalski SR, Plummer JL, et al. Fentanyl blood concentration-analgesic response relationship in the treatment of post-operative pain. Anesth Analg 1988; 67: 329-37
14. Smith KJ, Miller AJ, McKellar J, et al. Morphine at gramme doses: kinetics, dynamics and clinical need. Postgrad Med J 1991; 67 Suppl. 2: S55-9
15. Kaiko RF, Grandy RP, Oshlack B, et al. The United States experience with oral controlled-release morphine (MS Contin tablets): Pts I and II. Review of nine dose titration studies and clinical pharmacology of 15mg, 30mg, 60mg, and 100mg tablet strengths in normal subjects. Cancer 1989; 63: 2348-54
16. Jones R, Hale E, Talomsin L, et al. Kapanol™ capsules: pellet formulation provides alternative methods of administration of sustanied release morphine sulfate. Clin Drug Invest 1996; 12: 88-93
17. Donnadieu S, Hernot N, Suard L. Oral administration of sustained release morphine sulfate granules in patients with pain and dysphagia associated with cancer. Clin Drug Invest 1997; 14 Suppl. 1: 43-52
18. Drake J, Kirkpatrick CT, Aliyar CA, et al. Effect of food on the comparative pharmacokinetics of modified-release morphine tablet formulations: Oramorph SR and MST Continus. Br J Clin Pharmacol 1996; 41: 417-20
19. Bourget P, Lesne-Hulin A, Quinquis-Desmaris V. Study of the bioequivalence of two controlled-release formulations of morphine. Int J Clin Pharmacol Ther 1995; 33: 588-94
20. Hunt TL, Kaiko RF. Comparison of the pharmacokinetic profiles of two oral controlled-release morphine formulations in healthy young adults. Clin Ther 1991; 13: 482-8
21. Maccarrone C, West RJ, Broomhead AF, et al. Single dose pharmacokinetics of Kapanol™, a new oral sustained-release morphine formulation. Drug Invest 1994; 7: 262-74
22. D'Emanuele A. Responsive polymeric drug delivery systems: meeting the patients needs. Clin Pharmacokinet 1996; 31: 241-5
23. De Bernardi M, De Bernardi K, Colombo P. Randomised crossover comparison of the pharmacokinetic profiles of two sustained release morphine sulfate formulations in patients with cancer related pain. Clin Drug Invest 1997; 14 Suppl. 1: 28-33
24. Aitkenhead AR, Pinnock CA, Smith G. Pharmacokinetics of two preparations of slow-release oral morphine sulfate in volunteers. Anesthesiol Rev 1988; 15: 31-3
25. US Food and Drug Administration. Guidance oral extended (controlled) release dosage forms in vivo bioequivalence and in vitro dissolution testing. Rockville (MD): Division of Bioequivalence, Office of Generic Drugs; Centre for Drug Evalution and Research, US Food and Drug Administration. 1993 Sep
26. Patnaik RN, Lesko LJ, Chen ML, et al. Individual bioequivalence: new concepts in the statistical assessment of bioequivalence metrics. Clin Pharmacokinet 1997; 33: 1-6
27. Schall R, Muller FR, Muller FO, et al. Bioequivalence of controlled-release calcium antagonists. Clin Pharmacokinet 1997; 32: 75-89
28. Bashaw ED, Kaiko RF, Grandy RP, et al. Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade. Int J Clin Pharmacol Ther 1995; 33: 524-9
29. Rosen S, Grandy R, Benziger D, et al. Minimal cimetidine effect on MS Contin® tablet pharmacokinetics [abstract no. 224]. 8th World Congress on Pain; 1996 Aug 17-22; Vancouver
30. Drake J, Horth CE, Crawford FE. A reply [letter]. Br J Clin Pharmacol 1996; 42: 646-7
31. Miller AJ, Smith KJ. Effect of food on the comparative pharmacokinetics of modified-release morphine tablet formulations, Oramorph SR and MST Continus [letter]. Br J Clin Pharmacol 1996; 42: 645
32. Aherne GW, Littleton P. Morphine-6-glucuronide, an important factor in interpreting morphine radio-immunoassays. Lancet 1985; 11: 210-1
33. Kaiko RF. The effect of food intake on the pharmacokinetics of sustained-release morphine sulfate capsules. Clin Ther 1997; 19: 296-303
34. Kaiko RF, Lazarus H, Cronin C, et al. Controlled-release morphine bioavailability (MS Contin® tablets) in the presence and absence of food. Hospice J 1990; 6: 17-30
35. Broomhead A, West R, Kadirgamanathan G, et al. Comparative bioavailability of sustained-release morphine sulfate capsules versus pellets. Clin Drug Invest 1997; 14: 137-45
36. Gourlay GK, Plummer JL, Cherry DA, et al. Influence of a high fat meal on the absorption of morphine from oral solutions. Clin Pharmacol Ther 1989; 46: 463-8
37. Gourlay GK, Plummer JL, Cherry DA, et al. The reproducibility of bioavailability of oral morphine from solution under fed and fasted conditions. J Pain Symptom Manage 1991; 6: 431-6
38. Poulain P, Hoskin PJ, Hanks GW, et al. Relative bioavailability of controlled-release morphine tablets (MST Continus) in cancer patients. Br J Anaesth 1988; 61: 569-74
39. Schobelock MJ, Shepard KV, Mosdell KW, et al. Multiple-dose pharmacokinetic evaluation of two formulations of sustained release morphine sulfate tablets. Curr Ther Res 1995; 56: 1009-21
40. Gourlay GK, Plummer JL, Cherry DA, et al. A comparison of Kapanol (a new sustained-release morphine formulation), MST Continus, and morphine solution in cancer patients: pharmacokinetics aspects of morphine and morphine metabolites. In: Gebhart GF, Hammond DL, Jensen TS, editors. Progress in pain research and management. Seattle (WA): IASP Press, 1994: 631-43
41. Hasselstrom J, Alexander N, Bringel C, et al. Single-dose and steady-state kinetics of morphine and its metabolites in cancer patients: a comparison of two oral formulations. Eur J Clin Pharmacol 1991; 40: 585-91
42. Hanks GW, Hanna M, Finlay I, et al. Efficacy and pharmacokinetics of a new controlled-release morphine sulfate 200mg tablet. J Pain Sympton Manage 1995; 10: 6-12
43. Gourlay GK, Cherry DA, Onley MM, et al. Pharmacokinetics and pharmacodynamics of twenty-four-hourly Kapanol compared to twelve-hourly MS Contin in the treatment of severe cancer pain. Pain 1997; 69: 295-302
44. Gourlay GK, Plummer JL, Cherry DA. Chronopharmacokinetic variability in plasma morphine concentrations following oral doses of morphine solution. Pain 1995; 61: 375-81
45. Barberi-Heyob M, Merlin JL, Poulain P, et al. Circadian variations in morphine and morphine-6-glucuronide pharmacokinetics after oral and subcutaneous administration: first results [abstract]. Eur J Cancer 1991; 27 Suppl. 2: 286
46. Kaiko R, Grandy R, Thomas G, et al. A single-dose study of the effect of food ingestion and timing of dose administration on the pharmacokinetic profile of 30-mg sustained release morphine sulfate tablets. Curr Ther Res 1990; 447: 869-78
47. Bass J, Shepard KV, Lee JW, et al. An evaluation of the effect of food on the oral bioavailability of sustained-release morphine sulfate tablets (Oramorph SR) after multiple doses. J Clin Pharmacol 1992; 32: 1003-7
48. Walsh TD, MacDonald N, Bruera E, et al. A controlled study of sustained-release morphine sulfate tablets in chronic pain from advanced cancer. Am J Clin Oncol 1992; 15: 268-72
49. Finn JW, Walsh TD, MacDonald N, et al. Placebo-blinded study of morphine sulfate sustained-release tablets and immediate-release morphine sulfate sulution in outpatients with chronic pain due to advanced cancer. J Clin Oncol 1993; 11: 967-72
50. Deschamps M, Band PR, Hislop TG, et al. The evaluation of analgesic effects in cancer patients as exemplified by a double-blind, crossover study of immediate-release versus controlled-release morphine. J Pain Symptom Manage 1992; 7: 384-92
51. Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: efficacy, and quality of life. J Pain Symptom Manage 1997; 13: 254-61
52. Broomhead A, West R, Eglinton L, et al. Comparative single-dose pharmacokinetics of sustained-release and modified-release morphine sulfate capsules under fed and fasting conditions. Clin Drug Invest 1997; 13: 162-70
53. O'Brien T, Mortimer PG, McDonald CJ, et al. A randomized crossover study comparing the efficacy and tolerability of a novel once-daily morphine preparation (MXL capsules) with MST Continus tablets in cancer patients with severe pain. Palliative Med 1997; 11: 475-82
54. Smith KJ, McKellar J, Sinclair KA, et al. The influence of food on the pharmacokinetics of morphine from MST Continus suspension [abstract no. 1004]. VIIth World Congress on Pain; 1993 Aug 22-27; Paris, 382
55. Kaiko RF, Fitzmartin RD, Thomas GB, et al. The bioavailability of morphine in controlled-release 30mg tablets per rectum compared with immediate-release 30mg rectal suppositories and controlled-release 30mg oral tablets. Pharmacotherapy 1992; 12: 107-13
56. Darke A, Moulin D, Provencher L, et al. Efficacy, safety and pharmacokinetics of controlled release morphine suppositories and tablets in cancer pain [abstract]. Clin Pharmacol Trier 1995; 57: 165
57. Campbell WI. Rectal controlled-release morphine: plasma levels of morphine and its metabolites following the rectal administration of MST Continus 100mg. J Clin Pharm Ther 1996; 21: 65-71
58. Wilkinson TJ, Robinson BA, Begg EJ, et al. Pharmacokinetics and efficacy of rectal versus oral sustained-release morphine in cancer patients. Cancer Chemother Pharmacol 1992; 31: 251-4
59. Babul N, Darke AC, Anslow JA, et al. Pharmacokinetics of two novel rectal controlled-release morphine formulations. J Pain Symptom Manage 1992; 7: 400-5
60. Bruera E, Fainsinger R, Spachynski K, et al. Steady-state pharmacokinetic evaluation of a novel, controlled-release morphine suppository and subcutaneous morphine in cancer pain. J Clin Pharmcol 1995; 35: 666-72
61. Nahata MC. Plasma concentrations of morphine in children with chronic pain-comparison of controlled release and regular morphine sulfate tablets. J Clin Pharm Ther 1991; 16: 193-5
62. Osborne R, Joel S, Trew D, et al. Morphine and metabolite behaviour after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther 1990; 47: 12-9
63. Van Dongen RTM, Crul BJP, Koopman-Kimenai PM, et al. Morphine and morphine-glucuronide concentrations in plasma and CSF during long-term administration of oral morphine. Br J Clin Pharmacol 1994; 38: 271-3
64. Wolff T, Samuelsson H, Hedner T. Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration. Pain 1995; 62: 147-54
65. Wahlstrom A, Winblad B, Bixo M, et al. Human brain metabolism of morphine and naloxone. Pain 1988; 35: 121-7
66. Faura CC, Collins SL, Moore RA, et al. Systematic review of factors affecting the ratios of morphine and its major metabolites. Pain 1998; 74: 43-53